News

Alzheimer’s disease biomarkers have limited association with each other


 

References

Cerebrospinal fluid levels of amyloid-beta1-42 and brain amyloid-beta PET imaging with florbetapir-fluorine-18 had a limited association with each other as biomarkers for Alzheimer’s disease in a cross-sectional analysis of scans and CSF samples taken within 30 days of each other, according to Dr. Jon Toledo and his associates.

The associations between CSF amyloid-beta1-42 levels and florbetapir PET scans were not linear. The correlation between the two was strongest in the middle range. There was a larger range of florbetapir scan standardized uptake value ratios at the higher end of scores on the Alzheimer Disease Assessment Scale–cognitive subscale, compared with CSF amyloid-beta1-42 levels, indicating that florbetapir PET scans could better predict cognition. The association between the two biomarkers was significantly modified by APOE genotype, and no association was found in longitudinal CSF amyloid-beta1-42 levels and standardized uptake value ratios, the investigators reported.

The study “findings are significant for understanding how to interpret CSF amyloid-beta1-42 levels and florbetapir PET amyloid-beta measures for diagnosis and for understanding the mechanisms of amyloid-beta amyloidosis,” the researchers concluded.Find the full study in JAMA Neurology (doi:10.1001/jamaneurol.2014.4829).

Recommended Reading

Leuprolide, acetylcholinesterase inhibitor combo hints at effectiveness for Alzheimer’s
MDedge Family Medicine
Overanticoagulation in AF boosts dementia risk
MDedge Family Medicine
Advisory panel: Advanced dementia patients need better access to end-of-life care
MDedge Family Medicine
Pathologic proteins in Alzheimer’s, Parkinson’s also collect in skin cells
MDedge Family Medicine
Gout may lower Alzheimer’s risk
MDedge Family Medicine
Consortium opens Alzheimer’s data to global research community
MDedge Family Medicine
GAO calls for expanded efforts to reduce antipsychotic use in older dementia patients
MDedge Family Medicine
Study identifies factors for minimizing the impact of Alzheimer’s genetic risk
MDedge Family Medicine
Autopsy studies verify flutemetamol’s ability to identify brain beta-amyloid
MDedge Family Medicine
Dose-related increase in mortality with antipsychotics in dementia
MDedge Family Medicine